143148-26-9

Upstream product

• 6456-74-2 Glycine tert-butyl ester 
• 75315-63-8 N-(benzyloxycarbonyl)succinimide 
• 16881-32-6 tert-butyl N-(benzyloxycarbonyl)glycinate 
• 106-95-6 allyl bromide 

Downstream Products

• 150107-61-2 N-<1-(2-Phenylaminoethyl)>-N-benzyloxycarbonyl-glycine t-butyl ester 
• 143148-27-0 N-<1-(2-Oxoethyl)>-N-benzyloxycarbonylglycine t-butyl ester 

Relevant academic research and scientific papers

COMPOSITION AND METHODS FOR TREATING CHRONIC KIDNEY DISEASE

This invention relates to the treatment of chronic kidney disease, including diabetic nephropathy, focal segmental glomerulosclerosis (FSGS), nephrotic syndrome, non-diabetic chronic kidney disease, renal fibrosis or acute kidney injury by the administrat

Alpha V integrin receptor antagonists

The present invention relates to novel imidazolidinone derivatives thereof, their synthesis, and their use as αv integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors αvβ3 and/or

γ-turn peptidomimetics as fibrinogen antagonists

This invention relates to a method of inhibiting platelet aggregation, and compounds which are mimics of the peptide sequence Arg-Gly-Asp.

The use of γ-turn mimetics to define peptide secondary structure

A novel γ-turn mimetic 2 has been prepared based on retro amide peptide design. Incorporation of this mimetic into linear peptide fibrinogen receptor antagonist 7 (GPIIb/IIIa receptor) affords the opportunity to test models of antagonist pharmacophore.